Abstract:figure legend Morning exercise and pre‐breakfast metformin interact to reduce glycaemia in people with type 2 diabetes. Exercise is recommended in the treatment of type 2 diabetes and can improve insulin sensitivity. However, previous evidence suggests that exercise at different times of the day in people with type 2 diabetes may have opposing outcomes on glycaemia. Metformin is the most commonly prescribed initial pharmacological intervention in type 2 diabetes, and may alter adaptions to exercise. It is unknown if there is an interaction between metformin and diurnal exercise outcomes. We aimed to investigate glycaemic outcomes of moderate intensity morning vs. evening exercise in people with type 2 diabetes being prescribed metformin monotherapy. In this study, nine males and nine females with type 2 diabetes undergoing metformin monotherapy (age 61 ± 8.2 years, mean ± SD) completed a 16‐week crossover trial including 2‐week baseline recording, 6 weeks randomly assigned to a morning exercise (07.00–10.00 h) or evening exercise (16.00–19.00 h) and a 2‐week wash‐out period. Exercise arms consisted of 30 min of walking at 70% of estimated max heart rate every other day. Glucose levels were measured with continuous glucose monitors and activity measured by wrist‐worn monitors. Food‐intake was recorded by 4‐day food diaries during baseline, first and last 2 weeks of each exercise arm. There was no difference in exercise intensity, total caloric intake or total physical activity between morning and evening arms. As primary outcomes, acute (24 h) glucose area under the curve (AUC), was lower (P = 0.02) after acute morning exercise (180.6 ± 68.4 mmol/l) compared to baseline (210.3 ± 76.7 mmol/l); and there were no differences identified for glucose (mmol/l) between baseline, morning and evening exercise at any specific time point when data were analysed with two‐way ANOVA. As secondary outcomes, acute glucose AUC was significantly lower (P = 0.01) in participants taking metformin before breakfast (152.5 ± 29.95 mmol/l) compared with participants taking metformin after breakfast (227.2 ± 61.51 mmol/l) only during the morning exercise arm; and during weeks 5–6 of the exercise protocol, glucose AUC was significantly lower (P = 0.04) for participants taking metformin before breakfast (168.8 ± 15.8 mmol/l), rather than after breakfast (224.5 ± 52.0 mmol/l), only during morning exercise. Our data reveal morning moderate exercise acutely lowers glucose levels in people with type 2 diabetes being prescribed metformin. This difference appears to be driven by individuals that consumed metformin prior to breakfast rather than after breakfast. This beneficial effect upon glucose levels of combined morning exercise and pre‐breakfast metformin persisted through the final 2 weeks of the trial. Our findings suggest that morning moderate intensity exercise combined with pre‐breakfast metformin intake may benefit the management of glycaemia in people with type 2 diabetes. Key points Morning moderate exercise acutely lowers glucose levels in people with type 2 diabetes being prescribed metformin. This difference appears to be driven by individuals that consumed metformin prior to breakfast rather than after breakfast. Morning exercise combined with pre‐breakfast metformin persistently reduced glucose compared to morning exercise combined with post‐breakfast metformin through the final week (week 6) of the intervention. Our study suggests it may be possible to make simple changes to the time that people with type 2 diabetes take metformin and perform exercise to improve their blood glucose.

Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes.

Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes

The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial

Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport

Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients

The Beneficial Effect Of Metformin On Beta-Cell Function In Non-Obese Chinese Subjects With Newly Diagnosed Type 2 Diabetes

Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin

1362-P: the Long-Term Cardiovascular Effects of Metformin on Patients with Newly Diagnosed Type 2 Diabetes

546-P: Effects of Metformin on Heart Rate Variability in Adolescents with Type 1 Diabetes: A Secondary Analysis of a Randomized Crossover-Controlled Trial

Proceedings of the ACM SIGCOMM 2010 Conference on Applications, Technologies, Architectures, and Protocols for Computer Communications, New Delhi, India, August 30 -September 3, 2010

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.

Effects of plateau hypoxia on population pharmacokinetics and pharmacodynamics of metformin in patients with Type 2 diabetes

Morning exercise and pre‐breakfast metformin interact to reduce glycaemia in people with type 2 diabetes: a randomized crossover trial

Mechanism of glucose‐lowering by metformin in type 2 diabetes: Role of bile acids

Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes

Metformin associates with higher myocardial perfusion reserve and survival in type 2 diabetes mellitus patients

Increased hepatic gluconeogenesis and type 2 diabetes mellitus